Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Locally Advanced Pancreatic Cancer Market Size Changed, over the years?
The market size for locally advanced pancreatic cancer has seen a quick expansion in recent times. Expected to rise from $0.95 billion in 2024 to $1.05 billion in 2025, the market will have a compound annual growth rate (CAGR) of 10.9%. The escalation during the historic period is due to factors such as increased awareness of pancreatic cancer, advanced chemotherapy procedures, escalated usage of targeted therapies, a surge in pancreatic cancer cases, the evolution of combination treatment protocols, and improved supportive care alternatives.
How Much Will the Locally Advanced Pancreatic Cancer Market Be Worth in 2029?
In the coming years, a swift expansion is anticipated in the market size of locally advanced pancreatic cancer, projected to reach $1.57 billion by 2029, according to a compound annual growth rate (CAGR) of 10.5%. This growth during the forecast period can be ascribed to heightened awareness of pancreatic cancer, advancements in chemotherapy regimens, increased application of targeted therapies, a rise in pancreatic cancer incidence, the creation of combination treatment plans, and the improved care alternatives available. Key trends expected in the forecast timeframe include progress in immunotherapy, the introduction of targeted therapies, advancements in precise radiation methods, improved diagnostic imaging, the uptake of minimal invasive surgery, the use of artificial intelligence in treatment design, and progression in combination therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
Which is the Largest Company in the Locally Advanced Pancreatic Cancer Market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co
What Are the Main Market Drivers in the Locally Advanced Pancreatic Cancer Industry?
The rise in tobacco use is forecasted to fuel the growth of the market for locally advanced pancreatic cancer. Tobacco, a plant whose leaves are processed for consumption in items like cigarettes and cigars, is loaded with nicotine – an addictive substance linked to severe health conditions like cancer and heart diseases. Various factors such as easy availability, affordability, product promotion, and social acceptance in some places, as well as stress-driven smoking, propel the surge in tobacco use. This increase in tobacco intake is a primary risk influencer for locally advanced pancreatic cancer, contributing to the escalated occurrence of pancreatic abnormalities. For example, as per the Global Action to End Smoking, a US-based non-profit focused on research to halt the smoking epidemic, in 2022, nearly 62.9 million adults in the U.S were tobacco users, putting it at 4th place worldwide and at the top in the Americas. Furthermore, about 11.5% of American adults, which is approximately 28.3 million people smoked cigarettes, with a higher percentage seen in males (13.1%) compared to females (10.1%). As a result, the rise in tobacco use is a key driver propelling the growth of the locally advanced pancreatic cancer market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
How Is the Locally Advanced Pancreatic Cancer Market Segments Structured?
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy
What Strategic Trends Are Transforming the Locally Advanced Pancreatic Cancer Market?
Key players in the locally advanced pancreatic cancer market are concentrating on the creation of innovative products like orphan drugs, with the aim of bettering treatment alternatives, boosting patient results, and satisfying the unaddressed medical requirements tied to this aggressive disease. Orphan drugs, made for the treatment of rare ailments affecting a smaller population, are encouraged by regulatory bodies through benefits such as tax deductions and market exclusivity for their development. For instance, in January 2025, Actuate Therapeutics Inc., a biopharmaceutical firm in the US, declared that Elraglusib, its new GSK-3β inhibitor, obtained Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), which is a potential type of locally advanced pancreatic cancer. This distinction represents its potential to deal with a significant gap in treating this type of severe cancer, particularly after successful Phase 2 trial outcomes demonstrated considerable clinical progress and anti-tumor effects in patients with metastatic PDAC.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Locally Advanced Pancreatic Cancer Market?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214
This Report Delivers Insight On:
1. How big is the locally advanced pancreatic cancer market, and how is it changing globally?
2. Who are the major companies in the locally advanced pancreatic cancer market, and how are they performing?
3. What are the key opportunities and risks in the locally advanced pancreatic cancer market right now?
4. Which products or customer segments are growing the most in the locally advanced pancreatic cancer market?
5. What factors are helping or slowing down the growth of the locally advanced pancreatic cancer market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model